Drug intelligence / Profile preview

K9

Development stage: Preclinical
Lead developer: Inflammasome Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

K9 is an orally administered small molecule functioning as an inflammasome inhibitor. It is currently under investigation for the treatment of Thyroid Eye Disease (TED) and Diabetic Macular Edema (DME). Clinical trials are evaluating its safety and pharmacokinetics in healthy volunteers and its safety and efficacy in patients with these conditions.

Targets

Inflammasome (Inflammasomes)IL1B (Interleukin-1 beta)IL18 (Interleukin-18)

Beyond the preview

Go deeper on K9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K9.

Explore the full profile